MAZE
Maze Therapeutics, Inc.
$26.03
+2.20%
2026-05-08
About Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Key Fundamentals
Forward P/E
-7.49
EPS (TTM)
$-3.05
ROE
-47.5%
Profit Margin
0.0%
Debt/Equity
6.57
Price/Book
3.63
Market Cap
$1.44B
Avg Volume (10D)
566K
Recent Breakout Signals
No recent breakout signals detected for MAZE.
Recent Price Range (60 Days)
60D High
$53.65
60D Low
$24.80
Avg Volume
859K
Latest Close
$26.03
Get breakout alerts for MAZE
Sign up for Breakout Scanner to receive daily notifications when MAZE triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Maze Therapeutics, Inc. (MAZE) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors MAZE daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. MAZE operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.